Products for Research Use Only

Rosuvastatin

CAT: 0804-HY-17504A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17504A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].
CAS Number
287714-41-4
Product Name Alternative
ZD 4522
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Bacterial; HMG-CoA Reductase (HMGCR) ; Potassium Channel
Type
Reference compound
Related Pathways
Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Metabolic Disease; Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/rosuvastatin.html
Purity
99.67
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2
Molecular Formula
C22H28FN3O6S
Molecular Weight
481.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5 (2) : p. 437-44.|[2]Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101 (2) :868-78.|[3]Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16 (4) :1477-1488.|[4]Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62 (14) : p. 2075-85; discussion 2086-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
ACS Omega. 2025 Oct 29;10 (44) :52562–52575.|Biomed Pharmacother. 2025 Oct 21:192:118665.|Biosens Bioelectron. 2025 Nov 15:288:117807.|Eur J Pharmacol. 2023 Sep 15:955:175911.|Exp Ther Med. 2021 Oct;22 (4) :1189.|Front Cell Dev Biol. 2021 May 6;9:651579.|Front Oncol. 2021 May 10:11:595285.|J Inflamm Res. 2021 Apr 16:14:1537-1549.|J Nephropharmacol. 2025 Sep 20:e12798|Phytomedicine. 2024 Apr 10, 155621.|Vasc Endovasc Rev. 2025 Nov 7.|World J Methodol. 2025 Jun 20;15 (2) :99580.|Acta Pharmacol Sin. 2023 Jul;44 (7) :1416-1428.|Adv Sci (Weinh) . 2024 Jul 5:e2403451.|bioRxiv. 2024 November 08.|Cell Death Discov. 2024 May 29;10 (1) :263.|Cell Metab. 2025 Sep 2;37 (9) :1907-1925.e14.|Cell Signal. 2025 Jul:131:111753.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|MedComm (2020) . 2024 Aug 31;5 (9) :e681.|Pharm Res. 2025 Oct 27.|Phytomedicine. 2025 Jun 19:145:157014.